MedTrace Logo

Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management

NCT04925973 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-10-24

No results posted yet for this study

Summary

The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib.

Conditions

  • Ulcerative Colitis Acute

Interventions

DRUG

Tofacitinib 10 MG [Xeljanz]

Tofacitinib 10mg PO BID

Sponsors & Collaborators

  • University of Manitoba

    collaborator OTHER

  • University of British Columbia

    collaborator OTHER

  • McGill University

    collaborator OTHER

  • University of Alberta

    collaborator OTHER

  • McMaster University

    lead OTHER

Principal Investigators

  • Neeraj Narula, MD · McMaster University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2023-12-31
Completion
2023-12-31
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04925973 on ClinicalTrials.gov